NCT00707408View on ClinicalTrials.gov

High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 29, 2004

Study Completion Date

January 31, 2009

Conditions
AML
Interventions
DRUG

Imatinib

Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of response failure. Novartis provided supplies of imatinib for all patients included in the study.

Trial Locations (1)

44093

Nantes University Hopspital, Nantes

All Listed Sponsors
lead

Nantes University Hospital

OTHER

NCT00707408 - High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML) | Biotech Hunter | Biotech Hunter